- Neurocrine Biosciences (NBIX) plunges 29% AH as the 50mg dose of the small molecule VMAT2 inhibitor NBI-98854 misses the primary endpoint in a Phase 2b tardive dyskinesia study.
- A 100mg dose (which the company apparently thought would be the maximum tolerated dose but turned out to be well tolerated in the study) did produce a statistically significant reduction in tardive dyskinesia symptoms.
- The company decides to do the logical thing given the results: "We will now perform an additional Phase 2 study utilizing 100mg and higher doses." (PR)
Neurocrine Bio's NBI-98854 misses endpoint at low dose, higher dose shows promise
Sep 9 2013, 16:42 ET